NDRA - ENDRA Life Sciences rises on new U.S. patent for liver disease monitoring system

ENDRA Life Sciences (NASDAQ:NDRA) is trading 10% higher premarket after the United States Patent and Trademark Office issued a new patent for its Taeus’ radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. Thermo-Acoustic Enhanced UltraSound or Taeus combines radio frequency and ultrasound waves to measure fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and inflammation (NASH). The patent is titled “Broadband Applicator for Thermoacoustic Signal Generation.” The company said the patent will serve as the parent patent for future patent applications in China and Europe. NDRA's IP portfolio currently includes 48 patents issued globally. The company in March had won another patent for its Taeus product, titled 'Method and System for Determining a Material Type of an Object of Interest.'

For further details see:

ENDRA Life Sciences rises on new U.S. patent for liver disease monitoring system